Paper Details

  1. Home
  2. Paper Details

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience.

Author: FioreAna Patricia Peres, FragosoYára Dadalti, de OliveiraTatiana de Melo Gomes

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A study of Brazilian patients using glatiramer acetate, a drug for treating multiple sclerosis, found a 90% adherence rate to treatment. The main reason for discontinuation was medical decisions, not side effects or patient choice. This suggests that education and support programs can improve adherence to treatment for chronic conditions.
Paper Details　
Original Abstract of the Article :
Multiple sclerosis is a chronic disease characterized by demyelination and neurodegeneration of the central nervous system. Immunomodulatory treatment is possible at an early stage of the disease, and consists of injections of either beta-interferon or glatiramer acetate. The drugs are not curative,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770403/

データ提供：米国国立医学図書館（NLM）

Adherence to Glatiramer Acetate Treatment for Multiple Sclerosis: The Brazilian Experience

Multiple sclerosis (MS), a chronic neurological disorder, can significantly impact a person's quality of life. This study investigates the adherence to glatiramer acetate, an immunomodulatory treatment for MS, in a cohort of Brazilian patients. The study analyzed data from a patient program run by the pharmaceutical company that markets glatiramer acetate, evaluating the factors influencing treatment adherence.

High Adherence to Glatiramer Acetate Treatment in Brazil: A Positive Sign for MS Management

The study revealed a high rate of adherence to glatiramer acetate treatment in Brazil, with only 10% of patients discontinuing treatment. The main reason for discontinuation was medical decisions rather than side effects or patient choice. These findings indicate that a combination of appropriate healthcare, patient education, and a specific program for patients may contribute to better adherence to MS treatments.

Managing Multiple Sclerosis: The Importance of Adherence and Support

This study highlights the critical importance of adherence to MS treatments for optimal disease management. Factors such as healthcare access, patient education, and dedicated support programs can play a crucial role in promoting adherence and improving outcomes. This research underscores the importance of collaborative efforts between healthcare providers and patients to navigate the complexities of MS and its treatment.

Dr. Camel's Conclusion

Multiple sclerosis, a complex and challenging disease, requires a commitment to treatment for optimal management. This study reveals a high rate of adherence to glatiramer acetate treatment in Brazil, highlighting the positive impact of dedicated healthcare and support programs. Just as a desert traveler relies on their supplies and navigation skills, individuals with MS need access to appropriate treatment and support to navigate the challenges of their condition and maintain their quality of life.

Date :
  1. Date Completed 2011-07-14
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

19920943

DOI: Digital Object Identifier

PMC2770403

Related Literature

Article Analysis
・Side Effects of glatiramer injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.